Skip to main content
  • Is FAME 3 Trial Providing Answers or Raising More Questions?

    Recently, NEJM published the 1-year results of the FAME-3 study, where fractional flow reserve (FFR)-guided percutaneous coronary intervention (PCI) with current-generation drug-eluting stents (DES) was not found non-inferior to coronary artery by-pass grafting (CABG) in patients with three-vessel coronary artery disease  .

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details